NCCAM DHEA/Aging Trials In Development, Intramural Director Says
This article was originally published in The Tan Sheet
Executive Summary
NCCAM's Division of Intramural Research is composing study protocols to look at DHEA's effect on age-related health defects, Clinical Director Marc Blackman, MD, said at an advisory council meeting in Bethesda, Md. May 31.
You may also be interested in...
Mistletoe-Drug Interactions Will Be Subject Of NCCAM Intramural Study
The National Center for Complementary & Alternative Medicine's intramural division plans to study potential interactions between mistletoe and the cancer drug gemcitabine (Eli Lilly's Gemzar)
Mistletoe-Drug Interactions Will Be Subject Of NCCAM Intramural Study
The National Center for Complementary & Alternative Medicine's intramural division plans to study potential interactions between mistletoe and the cancer drug gemcitabine (Eli Lilly's Gemzar)
Mistletoe-Drug Interactions Will Be Subject Of NCCAM Intramural Study
The National Center for Complementary & Alternative Medicine's intramural division plans to study potential interactions between mistletoe and the cancer drug gemcitabine (Eli Lilly's Gemzar)